HER2+ status was identified in 7/82 (8.5%) patients with stage I–III adenocarcinoma who were treated with curative intent, and in 7/68 (10.3%) cases with stage IV adenocarcinoma. The gene discussed is ERBB2; the disease is adenocarcinoma.